BOLT Bolt Biotherapeutics, Inc. Insider Trading

SVP Finance Nemec buys 125 BOLT shares at $4.61; prior trades at BOLT showed 90d returns of +1567.7% and +1971.2%.

Sarah Nemec, Senior VP Finance and PAO, purchased 125 shares at $4.61 on 2025-12-05, increasing her holdings to 1,415 shares (+9.7%). Her prior two purchases at BOLT (2024-12-16 and 2024-06-06) delivered exceptional 90-day returns of +1567.7% and +1971.2% respectively, establishing a strong track record of well-timed entry points at this ticker. However, the company's fundamentals remain challenged: latest-quarter revenue was $2,169,000.00 with net income of $-7,144,000.00, annual revenue contracted -2.4%, and the company posted a negative full-year net income. The current price of $5.48 sits -46.3% from the 52-week high of $10.20 and only +18.8% above the $4.61 transaction price, reflecting continued weakness despite her demonstrated historical timing acumen at this ticker.

CEO Quinn bought 125 BOLT shares at $4.61; prior 4 of 5 BOLT buys posted strong 90d returns; near 52-week low with -46.3% decline from peak.

Quinn William P., serving as President, CEO and CFO, purchased 125 shares of Bolt Biotherapeutics at $4.61 on 2025-12-05, increasing holdings to 2,313 shares (a 5.7% increase). The stock is currently trading at $5.48, down 46.3% from its 52-week high of $10.20 and only $0.13 above the 52-week low of $4.51, placing this purchase near the floor of annual trading range. Historically, this insider's prior BOLT purchases on 2024-12-16, 2024-06-06, 2023-12-12, and 2023-12-06 all delivered strong 90-day returns (1567.7%, 1971.2%, 2573.7%, and 3045.8% respectively), establishing a pattern of well-timed entry points at this ticker. The company remains unprofitable with a net income of -$7,144,000.00 in its latest quarter, a market cap of $10,518,536.68, and negative annual revenue growth of -2.4%, creating a backdrop of fundamental distress that contextualizes the insider's accumulation activity at depressed valuations.

CEO Quinn buys 125 BOLT shares at $5.49; 5 prior buys at this ticker all returned +1567.7% to +3045.8% over 90 days.

Quinn William P., President, CEO and CFO, purchased 125 shares of Bolt Biotherapeutics on 2025-06-06 at $5.49, extending his holdings to 42,188 shares. His timing pattern at BOLT is noteworthy: all 5 prior purchases at this ticker generated substantially positive 90-day returns, ranging from +1567.7% to +3045.8%, with a 100% win rate over that window. The current stock price of $6.00 is -55.8% from its 52-week high of $13.59, suggesting a pronounced drawdown from recent peaks. However, the company's fundamentals remain challenged: it generated $1.8M in quarterly revenue with a -$8.6M net loss and -2.4% annual revenue growth, while holding a market cap of only $11.5M. The executive's purchase signal must be weighed against the material unprofitability and small scale of the enterprise, even as his historical execution at this ticker suggests an ability to identify inflection points.

CFO Sarah Nemec bought 125 shares at $5.49; prior BOLT buys delivered 1994.7% & 2162.3% 90d returns, but fundamentals deteriorating: -$8.6M net loss, $1.8M revenue, -2.4% YoY growth.

Sarah Nemec (Senior VP, Finance and PAO) purchased 125 shares at $5.49 on 2025-06-06, bringing holdings to 23.9K shares. Her prior trades at BOLT have been exceptionally well-timed: a buy on 2024-12-16 returned 1994.7% over 90 days, and a buy on 2024-06-06 returned 2162.3% over 90 days. However, this timing success must be weighed against deteriorating fundamentals: the latest quarter shows revenue of $1.8M and a net loss of $-8.6M, while annual revenue declined 2.4% year-over-year and the company remains unprofitable. The stock is currently 55.8% below its 52-week high of $13.59, trading at $6.00. This transaction signals potential conviction given her documented success at this ticker, yet the company's negative profitability and shrinking revenue raise questions about the sustainability of prior gains.

BOLT CEO Quinn purchases 5,000 shares ($2.8K blended at $0.57) with 52-week high of $26.60

Quinn William P., the President, CEO and CFO, executed 2 separate purchases totaling 5,000 shares for $2,834.75 (blended average $0.57), increasing holdings from 33.8K to 38.8K shares (+14.8%). The timing is notable: his prior 3 buys at BOLT were each followed by substantial 90-day gains (ranging from +1728.2% to +3045.8%), establishing a pattern of prescient entry points. The current price of $6.92 is -74.0% from the 52-week high of $26.60, and the stock has declined -26.4% over the prior 90 days. The company remains unprofitable (net income of $-15.2M on revenue of $1.1M) with flat annual revenue growth (-2.4%), creating a backdrop where insider accumulation by the CEO carries weight. Investors should examine whether this accumulation at depressed valuations reflects management's assessment of recovery potential or if it signals opportunistic repositioning amid fundamental weakness.

Senior VP Sarah Nemec purchases 5,000 shares in 2 transactions at $0.50 and $0.64 while stock down 74.0% from 52-week high.

Sarah Nemec, Senior VP Finance and PAO at Bolt Biotherapeutics, executed 2 separate purchases totaling 5,000 shares for $2,834.75 between December 2024 and June 2024, increasing her holdings by 56.4%. The purchases occurred at prices well below the current level of $6.92 and the 52-week high of $26.60. The timing of these transactions relative to the company's financial performance is notable: Bolt reported revenue of $1,141,000.00 in its latest quarter and a net loss of $-15,176,000.00 for its most recent full fiscal year, while revenue contracted 2.4% year-over-year. The insider buying at depressed valuation levels warrants attention, though the company's unprofitability and significant recent stock decline (-26.4% over 90 days) place this purchase in context of broader operational and market challenges.